- Medtronic Launches TYRX™ Envelope in India
admin Thu, 02/25/2021 - 15:13
India Medtronic Private Limited, a wholly owned subsidiary of Medtronic plc announced the launch of the TYRX™ Absorbable Antibacterial Envelope (TYRX Envelope) - an absorbable, single-use, antibacterial envelope designed to stabilize a cardiac implantable electronic device (CIED) or implanted neurostimulator while releasing antimicrobial agents over a minimum of seven days.
- Takeda Provides Updates on Phase 1/2 Clinical Trials of Novavax’ and Moderna’s COVID-19 Vaccine Candidates in Japan
admin Thu, 02/25/2021 - 15:06
Takeda Pharmaceutical Company Limited announced that the first subject was dosed in its Phase 1/2 immunogenicity and safety study of Novavax’ COVID-19 vaccine candidate (TAK-019) in Japan. Earlier this month, Takeda completed enrollment in the company’s Phase 1/2 immunogenicity and safety study of Moderna’s COVID-19 vaccine candidate (TAK-919) in Japan.
- Moderna sends COVID-19 booster shot for NIH testing
admin Thu, 02/25/2021 - 14:55
Moderna, Inc a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, announces that it has completed manufacturing of clinical trial material for its variant-specific vaccine candidate, mRNA-1273.351, against the SARS-CoV-2 variant known as B.1.351 first identified in the Republic of South Africa, and has shipped doses to the National Institutes of Health (NIH) for a Phase 1 clinical trial that will be led and funded by the NIH’s National Institute of Allergy and Infectious Diseases (NIAID).
- Government includes non-alcoholic fatty liver into National Program
admin Wed, 02/24/2021 - 16:57
Union Health Minister Dr. Harsh Vardhan on Monday announced inclusion of “non-alcoholic fatty liver disease” into the National Programme for Prevention & Control of Cancer, Diabetes, Cardiovascular Diseases and Stroke (NPCDCS), a move that will help manage the country’s burden of non-communicable diseases.
- Neurologists Identify Consistent Neuroinflammatory Response in ICH Patients
admin Tue, 02/23/2021 - 16:27
Understanding how the immune system responds to acute brain hemorrhage could open doors to identifying treatments for this devastating disease. However, up until now, there has been limited information on inflammation in the brain from human patients, especially during the first days after a hemorrhagic stroke.
This led a team of researchers to partner with a large clinical trial of minimally-invasive surgery to tackle defining the human neuroinflammatory response in living patients.
- New potential drug to treat SARS-CoV-2
admin Tue, 02/23/2021 - 16:21
A federally approved heart medication shows significant effectiveness in interfering with SARS-CoV-2 entry into the human cell host, according to a new study by a research team from Texas A&M University and The University of Texas Medical Branch (UTMB).
The medication bepridil, which goes by the trade name Vascor, is currently approved by the U.S. Food and Drug Administration (FDA) to treat angina, a heart condition.
- Astrazeneca withdraws Imfinzi indication in advanced bladder cancer in FDA
admin Tue, 02/23/2021 - 16:15
AstraZeneca announced the voluntary withdrawal of the Imfinzi (durvalumab) indication in the US for previously treated adult patients with locally advanced or metastatic bladder cancer. This decision was made in consultation with the Food and Drug Administration (FDA).
- Laipac Technology to Launch World’s First AI Rapid Antigen Test System
admin Tue, 02/23/2021 - 16:10
The LooK SPOT solution is an intelligent and innovative way to deploy technologies to better protect the health of people across the region. Being able to have a quick and accurate COVID-19 diagnosis can interrupt transmission, aid clinical management, and help proper allocation of resources to isolation.